Service Search Product Search Gene Search
HOME

SERVICES

• Protein Biotinylation Service • Custom Lysate Preparation Service • Immunogenicity Test Service > Anti-Drug Antibody (ADA) Evaluation Service > Neutralizing Antibody (NAb) Test Service • Anti-Drug Antibody (ADA) Evaluation Service • Neutralizing Antibody (NAb) Test Service • Thanksgiving Day Sale • Enzyme Target & Activator & Inhibitor Screening Service • GPCR Screening Service • Ion Channel Screening Service • Bio-layer Interferometry (BLI) Service • Electrophoretic Mobility Shift Assay (EMSA) Service • Transcription Factor Analysis > Electrophoretic Mobility Shift Assay (EMSA) Service > Chromatin Immunoprecipitation (ChIP) Assay Service > DNase I Footprinting Assay Service • Transporter Screening Service • Chromatin Immunoprecipitation (ChIP) Assay Service • Enzyme Activity Assay Service • DNase I Footprinting Assay Service • Co-Immunoprecipitation (Co-IP) • Surface plasmon resonance (SPR) Service • Pull Down Assay • Protein Mutant Library Construction • C1 Expression System • Protein Conjugation Service on Beads • Bacteria Expression • Yeast Expression • Mammalian Cell Expression • Insect Cell Expression • Animal-free Expression • Cell-free protein expression • Large-scale Protein Production • PEGylation Products and Services > Custom PEGylation Services > PEGylation Products • Basic Protein Characterization • Protein Labeling • Stable Cell Line Construction for Protein Expression • Protein Mutagenesis • Protein Interaction Analysis Services > Bio-layer Interferometry (BLI) Service > Co-Immunoprecipitation (Co-IP) > Surface plasmon resonance (SPR) Service > Pull Down Assay > Yeast Two-Hybrid Screening > Membrane-based Yeast Two-Hybrid Screening > CLIP-Seq Service > Protein Binding Site Mapping • Yeast Two-Hybrid Screening • Membrane-based Yeast Two-Hybrid Screening • Recombinant Protein or Antibody Production • Protein Expression Systems > Nicotiana tabacum Expression System > Bacterial Expression Systems(E. coli / Bacillus) > Yeast Expression Systems(P pastoris / S cerevisiae) > Baculovirus-insect Cell Expression Systems > Mammalian Expression Systems(CHO / 293) • PEGylation Services • Stable Cell Line Construction for Protein Expression • Process Development • cGMP Manufacturing • QC and QA • Bacterial Manufacturing • CLIP-Seq Service • Protein Binding Site Mapping • Quantum Dot Labeling • Protein Expression > Custom Lysate Preparation Service > C1 Expression System > Protein Co-expression Service in E. coli System > Protein Co-expression Service in Mammalian Cells > Trimeric Protein Production Service • Protein Co-expression Service in E. coli System • Protein Co-expression Service in Mammalian Cells • NovEgg Expression System • ADME/Tox Prediction • Pharmacophore Modeling • Screening and Profiling Services > Enzyme Target & Activator & Inhibitor Screening Service > GPCR Screening Service > Ion Channel Screening Service > Transporter Screening Service • Trimeric Protein Production Service • Incorporation of Bioorthogonal Handles > Incorporation of Unnatural Amino Acids > Incorporation of Unnatural Sugars > Direct Chemical Modification • Incorporation of Unnatural Amino Acids • Incorporation of Unnatural Sugars • Protein/peptide Crosslinking > Enzymatic Crosslinking Services > Photocrosslinking Services > Chemical Crosslinking Services • Enzymatic Crosslinking Services • Photocrosslinking Services • Chemical Crosslinking Services • Direct Chemical Modification • Protein-fluorophore Bioconjugation • Custom PEGylation Services • PEGylation Products • Target Protein Degradation - Proteolysis Targeting Chimera (PROTAC) • Induced Protein Degradation > Target Protein Degradation - Proteolysis Targeting Chimera (PROTAC) > Hydrophobic Tag Services > Destabilization Domains (DDs) • Hydrophobic Tag Services • Destabilization Domains (DDs) Nicotiana tabacum Expression System

CONTACT US

Tel: 1-631-448-8149
Fax: 1-631-938-8127

Immunogenicity Testing Services

Immunogenicity testing is a crucial part of biopharmaceutical development. More stringent regulations regarding immunogenicity assay performance necessitates the development of assays exhibiting excellent sensitivity, precision, free drug tolerance and minimal matrix effects. Immunogenicity assays can be applied in detection and confirmation of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) supporting nonclinical and clinical studies.

The development and validation of immunogenicity assays is under constant discussion within the industry. Based on our GLP-compliant service laboratories, Profacgen is involved in international workshops and has R&D programs to keep ahead of the latest developments in this area, so that we can best help our customers to accelerate their drug discovery and development programs.

Immunogenicity assays can be challenging due to interferences originating from the sample matrix, drug interference or target interference. In order to design a robust immunogenicity assay, it is important to start with the appropriate assay platform and high-quality reagents. There are two predominant strategies for proceeding through a biosimilar immunogenicity program based on the use of a single assay or two separate assays.

A single assay
One strategy to use for the immunogenicity program of a biosimilar is to employ one assay for the testing of all samples.  The assay is developed for both products and a limited set of parameters in validation should be evaluated including screening cut-point, specificity cut-point, precision, and drug tolerance for both products in order to ensure that the assay is capable of detecting antibodies to both the biosimilar and the reference product.

Two assays
The use of two assays for the assessment of immunogenicity for a biosimilar program will enable the direct comparison of immunogenicity rates for the biosimilar and the reference product.  The use of this approach entails a full validation of two separate assays, one for the detection of antibodies generated to the biosimilar and one for the detection of antibodies generated to the reference product.  This strategy is most useful when looking for an interchangeability designation.

A general  schematic of rapid immunogenicity tests
Figure 1. A general schematic of rapid immunogenicity tests.

Profacgen offers following immunogenicity testing services.

  Ligand Binding Assay
  Cell Based Assays
  Total Antibody Assay
  Neutralizing Antibody Assay
  Particle Size Characterization
  Critical Reagent Characterization
  Protein Aggregation Analysis

 

Profacgen’s immunogenicity team has developed and validated in vivo and in vitro assays for many of our biopharmaceutical clients to screen and quantify immunogenicity caused by anti-drug antibodies (ADAs) and impurities. Based on the risk profile of the biotherapeutic protein or antibody and its intended use, our team will work closely with our clients to develop a custom panel of immunogenicity assays. Please do not hesitate to contact us for more details about our membrane protein modeling service.

 

CONTACT US
Email: info@profacgen.com
Tel: 1-631-448-8149
Fax: 1-631-938-8127
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA